<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02334358</url>
  </required_header>
  <id_info>
    <org_study_id>LG-HAOS004</org_study_id>
    <nct_id>NCT02334358</nct_id>
  </id_info>
  <brief_title>Observational Study to Evaluate Long-term Safety and Biodegradability of YVOIRE Classic s</brief_title>
  <official_title>A Multi-center, Prospective and Observational Study to Evaluate Long-term Safety and Biodegradability of YVOIRE Classic s Injected Into the Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate long-term safety of YVOIRE classic s by incidence of adverse events including
      injection site local reactions and biodegradability
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Device-related Adverse Events</measure>
    <time_frame>Until subject reaching total biodegradation criterion (WSRS change) ; an expected average of 2 years.</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">503</enrollment>
  <condition>Correction of Nasolabial Folds</condition>
  <arm_group>
    <arm_group_label>YVOIRE Classic s</arm_group_label>
    <description>Treatment with YVOIRE Classic s</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>YVOIRE Classic s</intervention_name>
    <arm_group_label>YVOIRE Classic s</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subject who receive hyaluronic acid filler into the nasolabial folds
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects whose age is over 18 years old

          2. Subjects whose WSRS grade is equal or greater than 2

          3. Subjects must be willing and able to provide written informed consent

          4. Subjects who are scheduled to be treated with YVOIRE classic s for facial tissue
             augmentation to correct the nasolabial folds

        Exclusion Criteria:

          1. Subjects who are sensitive to hyaluronic acid or any excipients of YVOIRE classic s

          2. Subjects who have received permanent implantation (silicone, PAAG, PMMA, CaHA etc) on
             the nasolabial folds

          3. Subjects who have received nonpermanent aesthetic treatments, such as botulinum toxin
             injection or filler on the nasolabial folds within 9 months before screening

          4. Subjects who have received face lifting or plastic surgery on face within 9 months
             before screening

          5. Subjects who have received laser therapy on the nasolabial folds, chemical peeling or
             peeling on face within 3 months before the screening

          6. Subjects who have any skin diseases (including inflammation and skin cancer) or
             infectious diseases on the injection sites

          7. Subjects who tend to have hypertrophic scars

          8. Subjects with a history of streptococcal disease, severe allergy or anaphylaxis or
             bleeding disorders.

          9. Women in pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Q Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>January 4, 2015</study_first_submitted>
  <study_first_submitted_qc>January 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2015</study_first_posted>
  <results_first_submitted>November 9, 2018</results_first_submitted>
  <results_first_submitted_qc>November 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2019</results_first_posted>
  <last_update_submitted>November 9, 2018</last_update_submitted>
  <last_update_submitted_qc>November 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>YVOIRE Classic s</title>
          <description>YVOIRE Classic s</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="503"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="494"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>YVOIRE Classic s</title>
          <description>Treatment with YVOIRE Classic s
YVOIRE Classic s</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="494"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.44" spread="9.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="480"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Device-related Adverse Events</title>
        <time_frame>Until subject reaching total biodegradation criterion (WSRS change) ; an expected average of 2 years.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>YVOIRE Classic s</title>
            <description>Treatment with YVOIRE Classic s
YVOIRE Classic s</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Device-related Adverse Events</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Until subject reaching total biodegradation criterion (WSRS change) ; an expected average of 2 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>YVOIRE Classic s</title>
          <description>Treatment with YVOIRE Classic s
YVOIRE Classic s</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Extremity injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Polyps of duodenum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Cervical intraepithelial neoplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Leader</name_or_title>
      <organization>LG Chem</organization>
      <phone>82-2-6987-4148</phone>
      <email>sodam@lgchem.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

